With the advent of immunotherapy, antibody-drug conjugates, and other targeted therapies, impressive strides have been made to improve historically dismal outcomes among patients with triple-negative breast cancer (TNBC). With additional promising therapeutic strategies on the horizon, it is important to remain up to date with evolving evidence and guideline recommendations to optimize outcomes in this hard-to-treat population. Join us for Part 4 of our Breast Cancer Hot Topics series to learn how distinguished breast cancer clinicians approach triple-negative disease, including: practical approaches to biomarker testing in triple-negative breast cancer the latest clinical evidence supporting available and promising therapies in triple-negative breast cancer solving difficult case challenges. This activity is delivered in partnership with After Breast Cancer Diagnosis (ABCD).
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/evolving-treatment-landscape-triple-negative-breast-cancer-new-targeted
- Start Date: 2024-09-13 05:00:00
- End Date: 2024-09-13 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.25 hours
AMA PRA Category 1 Credit™️: 1.25 hours
Nursing: 1.25 hours
Pharmacy: 1.25 hours - MOC Credit Details: ABIM - 1.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AstraZeneca (Any division) - Amount: 11250.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 11250.0 - Is Kind Support: False Source: Gilead Sciences, Inc. - Amount: 8291.67 - Is Kind Support: False Source: Merck (Any division) - Amount: 8333.33 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology